Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H7Cl2NO |
| Molecular Weight | 228.075 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=C(O)C(Cl)=CC(Cl)=C2C=C1
InChI
InChIKey=GPTXWRGISTZRIO-UHFFFAOYSA-N
InChI=1S/C10H7Cl2NO/c1-5-2-3-6-7(11)4-8(12)10(14)9(6)13-5/h2-4,14H,1H3
DescriptionCurator's Comment: Description is created based on several sources, including http://www.sciencedirect.com/science/article/pii/S0022202X15488141 and http://www.ncbi.nlm.nih.gov/pubmed/140848
Curator's Comment: Description is created based on several sources, including http://www.sciencedirect.com/science/article/pii/S0022202X15488141 and http://www.ncbi.nlm.nih.gov/pubmed/140848
Chlorquinaldol is a halogenated hydroxyquinoline with properties similar to those of clioquinol. It is mainly applied topically in infected skin conditions and in vaginal infections. The product is applied for local treatment of cortico-sensitive dermatosis with moderately manifested superinfection, acute and subacute eczema, dermatitis, pyodermia, intertrigo, infected wounds, dermatomycosis, pemphigus in newborn. Chlorquinaldol is also used as antiseptic, fungistat, or deodorant. Chlorquinaldol is not commercially available in the U.S. but is used in other countries principally as an amebicide for nonspecific diarrheas and gynecologic infections. It is known most commonly under the proprietary name of Sterosan. Other trade names include Cynotherax, Gyno-Sterosan, Saprosan, Siogeno, Siosteran, Slosteran and Steroxin.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Escherichia coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/6236746 |
|||
Target ID: CHEMBL5192 Sources: http://www.ncbi.nlm.nih.gov/pubmed/24387280 |
10.1 µM [IC50] | ||
Target ID: Mycobacterium tuberculosis growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=17178795 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Chlorquinaldol Approved UseChlorquinaldol is primarily indicated in conditions like skin infections, vaginal infections. Launch Date2007 |
|||
| Curative | Gynosan Vaginal Pessary Approved UseGynosan Vaginal Pessary is used in the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms: skin infections, vaginal infections |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Therapeutic use of topical corticosteroids in the vesiculobullous lesions of incontinentia pigmenti. | 2009-12 |
|
| 3-[(E)-2-(5,7-Dichloro-8-hydroxy-quinolin-2-yl)vin-yl]-4-hydroxy-phenyl acetate. | 2009-02-11 |
|
| [Treatment of fungal infections of upper respiratory tract and ear]. | 2007 |
|
| [Gynalgin--one more opportunity in the treatment of bacterial vaginosis]. | 2007 |
|
| [Contact sensitization to pharmaceutic aids in dermatologic cosmetic and external use preparations]. | 2004-05 |
|
| Cutaneous drug reaction case reports: from the world literature. | 2002 |
|
| Contact cross-sensitization among quinolines. | 2001-08 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.sopharma.com/chlorquinaldol-h.php
Applied in a thin layer on affected skin areas 1-3 times daily. Therapy duration is up to 8 days.
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6236746
Chlorquinaldol displayed enhanced E. coli 205 bactericidal activity in human duodeno-pancreatic secretions with MIC 0.5ug/ml
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
D08AH02
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
||
|
WHO-ATC |
P01AA04
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
||
|
WHO-VATC |
QG01AC03
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
||
|
NDF-RT |
N0000185508
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
||
|
WHO-ATC |
G01AC03
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
||
|
WHO-ATC |
R02AA11
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
||
|
WHO-VATC |
QR02AA11
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
||
|
WHO-VATC |
QD08AH02
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
755830
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
2407
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
C77042
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
6301
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
m3466
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
N0000175629
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | Increased Histamine Release [PE] | ||
|
CHEMBL224325
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
N0000184306
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
N0000171131
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
CHLORQUINALDOL
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
200-789-3
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
3095
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
SUB06211MIG
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
72-80-0
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
100000092132
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
74500
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
DB13306
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
DTXSID3048998
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
D6VHC87LLS
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
D6VHC87LLS
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
D002750
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY | |||
|
215
Created by
admin on Mon Mar 31 17:36:17 GMT 2025 , Edited by admin on Mon Mar 31 17:36:17 GMT 2025
|
PRIMARY |
ACTIVE MOIETY